Showing 1541-1550 of 3038 results for "".
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Vertex Aims for “Virtual Clinic Visits” to Keep Ongoing Studies on Track Amid COVID-19 Pandemichttps://modernod.com/news/vertex-aims-for-virtual-clinic-visits-to-keep-ongoing-studies-on-track-amid-covid-19-pandemic/2477483/Vertex Pharmaceuticals said that due to the COVID-19 pandemic, the company is working with clinical trial sites to enable “virtual clinic visits” and home delivery of study drugs to ensure that ongoing trials continue as planned with the correct monitoring and procedures in place. How
- Visual Clinic’s ‘Safe Visits’ Aims to Help Eye Care Clinics Comply with New Post-COVID-19 Protocolshttps://modernod.com/news/visual-clinics-safe-visits-aims-to-help-eye-care-clinics-comply-with-new-post-covid-19-protocols/2477921/Visual Clinic announced the launch of its Safe Visits application. The software module provides ophthalmology and optometry practices with a streamlined care process that safely and efficiently guides patients and staff through appointments in the post-COVID-19 environment, according to a company
- CMS Eases Requirements for COVID-19 Tests, Boosts Payments for Telephonic Visitshttps://modernod.com/news/cms-eases-requirements-for-covid-19-tests-boosts-payments-for-telephonic-visits/2477699/The Trump administration is easing requirements on testing for COVID-19 to make it easier to administer drive-thru and “parking lot” testing facilities, according to a FierceHealthcare
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- American Academy of Ophthalmology Urges Members to Immediately Stop Routine Surgical and In-Office Visitshttps://modernod.com/news/american-academy-of-ophthalmology-urges-members-to-immediately-stop-routine-surgical-and-in-office-visits/2477412/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) stated that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately. The statement posted on the AAO website reads: “We now live and practice in a critically di
- Allergan to Present New Data from its Eye Care Portfolio at ASCRS 2022https://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-ascrs-2022/2480778/Allergan announced that it will present new data from its eye care portfolio at the 2022 ASCRS annual meeting being held April 22–26 in Washington, DC. Presentations will include new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only
- Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at ASCRShttps://modernod.com/news/orasis-pharmaceuticals-to-present-new-data-on-novel-presbyopia-candidate-at-ascrs/2480764/Orasis Pharmaceuticals announced that it will present new data on its novel eye drop candidate, CSF-1, at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) annual meeting being held April 22-26 in Washington, D.C. "We look forward to these present
- Novavax’s COVID-19 Vaccine Over 89% Effective in UK trial, Less So in South Africa Studyhttps://modernod.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/Novavax shares gained as much as 26% on Thursday after the company said its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary endpoint of a phase 3 trial in the UK, demonstrating an efficacy rate of over 89%, with high protection also seen against the fast-spreading UK variant.
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d